Symbols / ACRV Stock $1.76 +10.00% Acrivon Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
ACRV (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Peter Blume-Jensen M.D., Ph.D.
Exch · Country NGM · United States
Market Cap 75.33M
Enterprise Value -19.99M
Income -77.27M
Sales —
FCF (ttm) -39.28M
Book/sh 3.56
Cash/sh 2.28
Employees 74
Insider 10d —
IPO Nov 15, 2022
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.94
PEG —
P/S —
P/B 0.50
P/C —
EV/EBITDA 0.25
EV/Sales —
Quick Ratio 8.84
Current Ratio 8.98
Debt/Eq 2.53
LT Debt/Eq —
EPS (ttm) -2.00
EPS next Y -1.87
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-13
Earnings (prior) 2026-05-13
ROA -36.22%
ROE -60.39%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 42.80M
Shs Float 27.97M
Insider Own 14.94%
Instit Own 47.04%
Short Float 8.60%
Short Ratio 3.05
Short Interest 2.46M
52W High 3.56
vs 52W High -50.56%
52W Low 1.05
vs 52W Low 67.62%
Beta —
Impl. Vol. —
Rel Volume 0.51
Avg Volume 791.44K
Volume 399.98K
Target (mean) $11.50
Tgt Median $10.50
Tgt Low $7.00
Tgt High $19.00
# Analysts 6
Recom Strong_buy
Prev Close $1.60
Price $1.76
Change 10.00%
About

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$11.50
Mean price target
2. Current target
$1.76
Latest analyst target
3. DCF / Fair value
$-16.52
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.76
Low
$7.00
High
$19.00
Mean
$11.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-01-09 main Piper Sandler Overweight → Overweight $8
2025-11-25 reit HC Wainwright & Co. Buy → Buy $19
2025-08-14 main Oppenheimer Outperform → Outperform $8
2025-05-16 down Jones Trading Buy → Hold —
2025-05-15 main Oppenheimer Outperform → Outperform $9
2025-03-28 reit HC Wainwright & Co. Buy → Buy $19
2025-03-28 main Oppenheimer Outperform → Outperform $10
2025-03-26 reit Cantor Fitzgerald Overweight → Overweight —
2025-03-26 reit Citizens Capital Markets Market Outperform → Market Outperform $17
2025-03-26 main HC Wainwright & Co. Buy → Buy $19
2025-01-31 init Cantor Fitzgerald — → Overweight —
2024-11-14 main BMO Capital Outperform → Outperform $27
2024-11-14 reit HC Wainwright & Co. Buy → Buy $22
2024-09-16 reit JMP Securities Market Outperform → Market Outperform $17
2024-09-16 up Ladenburg Thalmann Neutral → Buy $16
2024-09-16 reit BMO Capital Outperform → Outperform $28
2024-09-16 reit HC Wainwright & Co. Buy → Buy $22
2024-08-13 reit HC Wainwright & Co. Buy → Buy $22
2024-05-15 reit BMO Capital Outperform → Outperform $25
2024-05-14 main HC Wainwright & Co. Buy → Buy $22
News
RSS: Latest ACRV news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-22 RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security — 3,888,888 $1.80 $6,999,998
2026-01-14 BLUME-JENSEN PETER Chief Executive Officer — 49,000 $1.68 $82,124
2026-01-14 LEVY ADAM D. Chief Financial Officer — 8,832 $1.70 $14,999
2026-01-13 DEVROE ERIC Chief Operating Officer — 10,000 $1.72 $17,218
2025-05-01 PERCEPTIVE ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 736,767 $1.34 $1,017,919
2025-04-29 PERCEPTIVE ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 1,519,952 $1.41 $2,744,946
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
84.11
-5.70%
89.20
+32.93%
67.10
+105.48%
32.66
Research And Development
59.99
-6.25%
63.99
+39.04%
46.02
+92.18%
23.95
Selling General And Administration
24.12
-4.30%
25.21
+19.58%
21.08
+142.06%
8.71
General And Administrative Expense
24.12
-4.30%
25.21
+19.58%
21.08
+142.06%
8.71
Salaries And Wages
—
18.10
+23.83%
14.62
+188.46%
5.07
Other Gand A
24.12
-4.30%
25.21
+290.20%
6.46
+77.47%
3.64
Total Expenses
84.11
-5.70%
89.20
+32.93%
67.10
+105.48%
32.66
Operating Income
-84.11
+5.70%
-89.20
-32.93%
-67.10
-105.48%
-32.66
Total Operating Income As Reported
-84.11
+5.70%
-89.20
-32.93%
-67.10
-105.48%
-32.66
EBITDA
-82.76
+6.16%
-88.19
-32.49%
-66.57
-106.13%
-32.29
Normalized EBITDA
-82.76
+6.16%
-88.19
-32.49%
-66.57
-106.13%
-32.29
Reconciled Depreciation
1.36
+34.79%
1.01
+87.69%
0.54
+47.25%
0.36
EBIT
-84.11
+5.70%
-89.20
-32.93%
-67.10
-105.48%
-32.66
Total Unusual Items
—
—
—
—
Total Unusual Items Excluding Goodwill
—
—
—
—
Net Income
-77.91
+3.29%
-80.56
-33.40%
-60.39
-93.76%
-31.17
Pretax Income
-77.91
+3.29%
-80.56
-33.40%
-60.39
-93.76%
-31.17
Net Non Operating Interest Income Expense
6.48
-29.58%
9.20
+30.75%
7.04
—
Net Interest Income
6.48
-29.58%
9.20
+30.75%
7.04
—
Interest Income Non Operating
6.48
-29.58%
9.20
+30.75%
7.04
—
Interest Income
6.48
-29.58%
9.20
+30.75%
7.04
—
Other Income Expense
-0.27
+51.61%
-0.56
-73.29%
-0.32
-121.61%
1.49
Other Non Operating Income Expenses
-0.27
+51.61%
-0.56
-73.29%
-0.32
-121.61%
1.49
Gain On Sale Of Security
—
—
—
—
Tax Rate For Calcs
0.00
-100.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-77.91
+3.29%
-80.56
-33.40%
-60.39
-93.76%
-31.17
Net Income From Continuing Operation Net Minority Interest
-77.91
+3.29%
-80.56
-33.40%
-60.39
-93.76%
-31.17
Net Income From Continuing And Discontinued Operation
-77.91
+3.29%
-80.56
-33.40%
-60.39
-93.76%
-31.17
Net Income Continuous Operations
-77.91
+3.29%
-80.56
-33.40%
-60.39
-93.76%
-31.17
Normalized Income
-77.91
+3.29%
-80.56
-33.40%
-60.39
-93.76%
-31.17
Net Income Common Stockholders
-77.91
+3.29%
-80.56
-33.40%
-60.39
-93.76%
-31.17
Diluted EPS
—
-2.38
+13.14%
-2.74
+63.76%
-7.56
Basic EPS
—
-2.38
+13.14%
-2.74
+63.76%
-7.56
Basic Average Shares
—
33.79
+53.06%
22.08
+435.63%
4.12
Diluted Average Shares
—
33.79
+53.06%
22.08
+435.63%
4.12
Diluted NI Availto Com Stockholders
-77.91
+3.29%
-80.56
-33.40%
-60.39
-93.76%
-31.17
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
129.72
-34.02%
196.59
+42.18%
138.26
-23.71%
181.23
Current Assets
120.44
-33.69%
181.63
+40.05%
129.69
-1.82%
132.09
Cash Cash Equivalents And Short Term Investments
118.58
-33.93%
179.48
+40.82%
127.46
-0.23%
127.75
Cash And Cash Equivalents
41.50
+4.22%
39.82
+10.56%
36.02
+22.01%
29.52
Other Short Term Investments
77.08
-44.81%
139.66
+52.73%
91.44
-6.91%
98.23
Prepaid Assets
—
—
—
—
Other Current Assets
1.86
-13.31%
2.15
-3.80%
2.23
-48.57%
4.34
Total Non Current Assets
9.27
-38.02%
14.96
+74.49%
8.57
-82.55%
49.13
Net PPE
7.42
-7.59%
8.03
+1.48%
7.91
+15.24%
6.86
Gross PPE
10.73
+7.48%
9.99
+12.67%
8.86
+21.72%
7.28
Accumulated Depreciation
-3.32
-69.11%
-1.96
-105.23%
-0.96
-127.62%
-0.42
Machinery Furniture Equipment
7.29
+14.37%
6.38
+103.87%
3.13
+24.48%
2.51
Construction In Progress
0.92
+1479.31%
0.06
-95.57%
1.31
0.00
Other Properties
2.53
-28.90%
3.55
-19.76%
4.43
-7.15%
4.77
Investments And Advances
0.00
-100.00%
5.09
0.00
-100.00%
41.88
Non Current Deferred Assets
1.65
+0.36%
1.65
+556.18%
0.25
0.00
Other Non Current Assets
0.20
+2.53%
0.20
-52.17%
0.41
+6.70%
0.39
Total Liabilities Net Minority Interest
17.20
-13.14%
19.80
+16.00%
17.07
+58.78%
10.75
Current Liabilities
15.66
-9.00%
17.21
+29.40%
13.30
+104.16%
6.52
Payables And Accrued Expenses
8.93
-16.51%
10.70
+24.92%
8.57
+180.03%
3.06
Payables
2.28
+200.40%
0.76
-84.98%
5.05
+458.41%
0.90
Accounts Payable
2.28
+200.40%
0.76
-84.98%
5.05
+458.41%
0.90
Current Accrued Expenses
6.66
-33.05%
9.94
+182.63%
3.52
+63.25%
2.15
Pensionand Other Post Retirement Benefit Plans Current
5.56
+1.87%
5.46
+41.35%
3.86
+45.00%
2.66
Current Debt And Capital Lease Obligation
1.17
+10.88%
1.06
+20.52%
0.88
+20.80%
0.73
Current Capital Lease Obligation
1.17
+10.88%
1.06
+20.52%
0.88
+20.80%
0.73
Current Deferred Liabilities
—
—
0.00
-100.00%
0.07
Current Deferred Revenue
—
—
0.00
-100.00%
0.07
Total Non Current Liabilities Net Minority Interest
1.54
-40.61%
2.59
-31.30%
3.77
-11.05%
4.24
Long Term Debt And Capital Lease Obligation
1.54
-40.61%
2.59
-31.30%
3.77
-11.05%
4.24
Long Term Capital Lease Obligation
1.54
-40.61%
2.59
-31.30%
3.77
-11.05%
4.24
Preferred Securities Outside Stock Equity
—
—
—
0.00
Stockholders Equity
112.52
-36.35%
176.79
+45.87%
121.19
-28.91%
170.47
Common Stock Equity
112.52
-36.35%
176.79
+45.87%
121.19
-28.91%
170.47
Capital Stock
0.03
+0.00%
0.03
+34.78%
0.02
+4.55%
0.02
Common Stock
0.03
+0.00%
0.03
+34.78%
0.02
+4.55%
0.02
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
31.65
+1.34%
31.23
+38.67%
22.52
+2.75%
21.92
Ordinary Shares Number
31.65
+1.34%
31.23
+38.67%
22.52
+2.75%
21.92
Additional Paid In Capital
387.25
+3.74%
373.28
+57.06%
237.68
+4.90%
226.58
Retained Earnings
-274.88
-39.55%
-196.98
-69.19%
-116.42
-107.77%
-56.03
Gains Losses Not Affecting Retained Earnings
0.11
-75.17%
0.45
+638.55%
-0.08
+12.63%
-0.10
Other Equity Adjustments
0.11
-75.17%
0.45
+638.55%
-0.08
+12.63%
-0.10
Total Equity Gross Minority Interest
112.52
-36.35%
176.79
+45.87%
121.19
-28.91%
170.47
Total Capitalization
112.52
-36.35%
176.79
+45.87%
121.19
-28.91%
170.47
Working Capital
104.78
-36.27%
164.41
+41.26%
116.39
-7.32%
125.58
Invested Capital
112.52
-36.35%
176.79
+45.87%
121.19
-28.91%
170.47
Total Debt
2.71
-25.68%
3.65
-21.51%
4.64
-6.39%
4.96
Capital Lease Obligations
2.71
-25.68%
3.65
-21.51%
4.64
-6.39%
4.96
Net Tangible Assets
112.52
-36.35%
176.79
+45.87%
121.19
-28.91%
170.47
Tangible Book Value
112.52
-36.35%
176.79
+45.87%
121.19
-28.91%
170.47
Available For Sale Securities
—
5.09
—
—
Current Notes Payable
—
—
—
—
Derivative Product Liabilities
—
—
—
—
Investmentin Financial Assets
0.00
-100.00%
5.09
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-63.66
+3.05%
-65.67
-54.00%
-42.64
-41.58%
-30.12
Cash Flow From Continuing Operating Activities
-63.66
+3.05%
-65.67
-54.00%
-42.64
-41.58%
-30.12
Net Income From Continuing Operations
-77.91
+3.29%
-80.56
-33.40%
-60.39
-93.76%
-31.17
Depreciation Amortization Depletion
1.36
+34.79%
1.01
+87.69%
0.54
+47.25%
0.36
Depreciation
1.36
+34.79%
1.01
+87.69%
0.54
+47.25%
0.36
Depreciation And Amortization
1.36
+34.79%
1.01
+87.69%
0.54
+47.25%
0.36
Other Non Cash Items
1.03
+10.19%
0.93
+19.79%
0.78
+6.43%
0.73
Stock Based Compensation
14.72
+3.02%
14.29
+22.98%
11.62
+431.72%
2.19
Operating Gains Losses
—
—
—
—
Gain Loss On Investment Securities
—
—
—
—
Change In Working Capital
-2.43
-199.51%
2.44
-70.04%
8.14
+631.20%
-1.53
Change In Prepaid Assets
0.19
-19.83%
0.24
-88.77%
2.11
+159.62%
-3.54
Change In Payables And Accrued Expense
-1.82
-140.97%
4.43
-34.61%
6.78
+153.63%
2.67
Change In Accrued Expense
-3.35
-141.80%
8.02
+152.79%
3.17
+8.70%
2.92
Change In Payable
1.54
+142.83%
-3.59
-199.36%
3.61
+1573.06%
-0.24
Change In Account Payable
1.54
+142.83%
-3.59
-199.36%
3.61
+1573.06%
-0.24
Change In Other Current Assets
0.14
+111.62%
-1.18
0.00
—
Change In Other Current Liabilities
-0.94
+11.28%
-1.05
-39.92%
-0.75
-13.04%
-0.67
Investing Cash Flow
66.10
+227.68%
-51.77
-202.08%
50.72
+135.80%
-141.68
Cash Flow From Continuing Investing Activities
66.10
+227.68%
-51.77
-202.08%
50.72
+135.80%
-141.68
Net PPE Purchase And Sale
-1.67
+39.70%
-2.77
-114.91%
-1.29
+40.54%
-2.17
Purchase Of PPE
-1.67
+39.70%
-2.77
-114.91%
-1.29
+40.54%
-2.17
Capital Expenditure
-1.67
+39.70%
-2.77
-114.91%
-1.29
+40.54%
-2.17
Net Investment Purchase And Sale
67.77
+238.30%
-49.00
-194.23%
52.01
+137.28%
-139.51
Purchase Of Investment
-81.73
+59.72%
-202.93
-258.98%
-56.53
+62.36%
-150.18
Sale Of Investment
149.50
-2.87%
153.92
+41.82%
108.53
+917.37%
10.67
Financing Cash Flow
-0.75
-100.62%
121.03
+7888.10%
-1.55
-101.53%
101.71
Cash Flow From Continuing Financing Activities
-0.75
-100.62%
121.03
+7888.10%
-1.55
-101.53%
101.71
Net Issuance Payments Of Debt
—
—
—
—
Issuance Of Debt
—
—
—
—
Short Term Debt Issuance
—
—
—
—
Net Short Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
0.00
-100.00%
70.00
0.00
-100.00%
104.46
Proceeds From Stock Option Exercised
0.00
-100.00%
60.09
+7653.94%
0.78
+3129.17%
0.02
Net Other Financing Charges
-0.75
+91.72%
-9.06
-289.14%
-2.33
+16.01%
-2.77
Changes In Cash
1.69
-53.00%
3.59
-45.00%
6.52
+109.31%
-70.08
Beginning Cash Position
40.02
+9.85%
36.43
+21.81%
29.91
-70.09%
99.99
End Cash Position
41.70
+4.21%
40.02
+9.85%
36.43
+21.81%
29.91
Free Cash Flow
-65.33
+4.53%
-68.44
-55.79%
-43.93
-36.07%
-32.28
Amortization Of Securities
-0.44
+88.43%
-3.78
-13.66%
-3.32
-376.07%
-0.70
Common Stock Issuance
0.00
-100.00%
70.00
0.00
-100.00%
104.46
Issuance Of Capital Stock
0.00
-100.00%
70.00
0.00
-100.00%
104.46
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category